Dr. Ewelina Kulikowski reports

RESVERLOGIX ANNOUNCES PUBLICATION OF SCIENTIFIC JOURNAL ARTICLES RELATING TO APABETALONE'S PREVENTION OF HEART FAILURE

Resverlogix Corp. has published two new scientific journal articles on mechanisms relating to heart failure prevention by the company's lead clinical candidate, apabetalone.

"One of the most striking findings from BETonMACE was the reduction in heart failure hospitalizations among apabetalone-treated patients," said Dr. Ewelina Kulikowski, PhD, chief scientific officer at Resverlogix. "These publications provide new insights into the biology that may underlie this benefit, suggesting that apabetalone reduces metabolic dysfunction and the formation of damaging scar tissue. Together, these findings strengthen our understanding of apabetalone's potential to protect the heart and improve outcomes for patients."

Metabolic shift improves liver and heart function

The first article, titled: "Apabetalone Drives a Metabolic Shift Towards Ketogenesis and Reduces Liver Steatosis in Diet-Induced Obesity Mice," was published in the peer-reviewed journal Biomedicines and authored by a team of Resverlogix researchers including lead author Laura Tsujikawa.

Key highlights:

• Obesity is associated with metabolic dysfunction that affects multiple organs, contributing to fatty liver disease and heart failure.
• Using a diet-induced obesity mouse model, researchers demonstrated a beneficial metabolic shift in apabetalone-treated mice, exemplified by an increase in circulating ketone levels.
• This metabolic shift reduced lipid accumulation in the liver of treated mice and lowered levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) -- a diagnostic marker of heart failure.
• These findings suggest that apabetalone may address underlying drivers of metabolic dysfunction, providing further support for its potential to reduce the burden of heart failure in patients, and introducing a rationale for its treatment of fatty liver disease.

Apabetalone prevents fibrosis linked to heart failure

The second article, titled: "BET Inhibitor Apabetalone Suppresses the Fibrotic Activation of Cardiac Fibroblasts Associated with Heart Dysfunction," was published in the peer-reviewed journal Biomedicine & Pharmacotherapy, and written by lead authors Dr. Sylwia Wasiak and Dr. Dean Gilham.

Key highlights:

• Following cardiac injury, such as a heart attack, the body can produce too much extracellular matrix (ECM) (the primary component of scar tissue), which can impair the heart's ability to stretch and contract.
• Cardiac fibroblasts are a type of cells that specialize in regulating ECM deposition and activate in response to cardiac injury.
• Researchers found that treatment with apabetalone reduced the activation of cardiac fibroblasts and their deposition of ECM.
• These findings suggest that apabetalone may help limit the formation of damaging scar tissue following cardiac injury, potentially helping patients preserve heart function and align with observed reductions in heart failure hospitalizations.

About apabetalone

Apabetalone (RVX-208) is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes.

Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes representing a new way to treat chronic disease. Apabetalone is the only drug of its class that is well tolerated for chronic administration, with an established safety record across multiple human clinical trials, totalling over 4,200 patient-years of safety data.

Cardiology

Apabetalone is the first therapy of its kind to receive breakthrough therapy designation from the United States Food and Drug Administration for a major cardiovascular indication. This followed the groundbreaking findings from its phase 3 study, BETonMACE, which showed apabetalone may prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have Type 2 diabetes mellitus.

About Resverlogix Corp.

Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. The company aims to improve patients' lives by restoring biological functions -- altered by serious illnesses such as cardiovascular disease -- back to a healthier state.

The company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities and post COVID-19 conditions.

We seek Safe Harbor.